Business
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR
Itolizumab was associated with high clinical response rates at Day 15 and 29 Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169
About this update from Equillium, Inc.
[{"type":"text","content":"\nItolizumab was associated with high clinical response rates at Day 15 and 29\n\nResponders were able to taper steroids by 70% at Day 29 and 99% at Day 169\n\nItolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host disease\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an oral presentation was given yesterday afternoon at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research.\n\nThe oral presentation, given by Dr. John Koreth, associate professor of medicine, Dana Farber Cancer Institute, Harvard Medical School, highlights positive final study results, including long-term follow-up data for up to one year, from EQUATE (NCT03763318), a Phase 1b study of itolizumab in combination with corticosteroids (CS) to treat subjects with newly diagnosed severe acute graft-versus-host disease (aGVHD). The data demonstrate promising outcomes in subjects with severe aGVHD. Equillium has since initiated EQUATOR (NCT05263999), a pivotal Phase 3 study of itolizumab as a potential initial therapy for aGVHD in combination with CS.\n\n“Acute GVHD is a potentially lethal condition with no drugs approved for the first-line treatment setting,” said Dr. Koreth. “Twelve-month findings from the study support the potential clinical value of itolizumab as an initial treatment for patients with high-risk aGVHD, demonstrate high complete response rates that are both rapid and durable and compare favorably to historical data with corticosteroid therapy alone. Importantly, these findings demonstrated that responders to itolizumab treatment had a clinically meaningful reduction in the use of corticosteroid of ninety-nine percent at six months.”\n\nTitle: Final Safety and Efficacy Results from EQUATE, an Open-Label Study Evaluating Itolizumab, a Novel Targeted anti-CD6 Therapy, in Newly Diagnosed Acute Graft-Versus-Host Disease\nPresenting Author: Dr. John Koreth\nAbstract ID Number: 36\nAssigned Session: Oral Abstract - Session E: GVHD - Clinical\n\nKey Highlights, Summary and Conclusions from Presentation:\n\n\nItolizumab treatment in combinat...